Dangerous Drug: Pramlintide Acetate



Dangerous Drug: Pramlintide Acetate





(pram’ lin tyde)

Symlin

PREGNANCY CATEGORY C


Drug Classes

Amylinomimetic

Antidiabetic


Therapeutic Actions

A synthetic analogue of human amylin, a hormone produced by the beta cells in the pancreas that helps to control glucose levels in the postprandial period; modulates gastric emptying, causes a feeling of fullness or satiety, prevents the postprandial rise in serum glucagon levels all leading to lower serum glucose levels.


Indications



  • Adjunct treatment in patients with type 1 diabetes who use mealtime insulin and who have failed to achieve desired glucose control despite optimal insulin therapy


  • Adjunct treatment in type 2 diabetes patients who use mealtime insulin and who have failed to achieve desired glucose control despite optimal insulin therapy with or without a concurrent sulfonylurea or metformin



Available Forms

Solution for injection—1.5 mg/1.5 mL, 2.7 mg/2.7 mL


Dosages

Adults



  • Type 2 diabetes: Initially, 60 mcg by subcutaneous injection immediately prior to major meals. Dose may be increased to 120 mcg
    if needed and tolerated. Dosage of oral drugs and insulins will need to be reduced, usually by 50% based on patient response.


  • Type 1 diabetes: Initially, 15 mcg by subcutaneous injection immediately before major meals, titrate at 15 mcg increments to a maintenance dose of 30 or 60 mcg as tolerated. Dosage of insulins will need to be reduced by 50% and the patient must be monitored closely to achieve optimal glucose control.


Pharmacokinetics

















Route Onset Peak Duration
Subcut. Rapid 21 min 3 hr

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 21, 2016 | Posted by in NURSING | Comments Off on Dangerous Drug: Pramlintide Acetate

Full access? Get Clinical Tree

Get Clinical Tree app for offline access